Thomas Schurpf
Company: Scholar Rock
Job title: Associate Director
Seminars:
Inhibition of TGFβ1 Activation with SRK-181 to Overcome Primary Resistance to Checkpoint Inhibition Therapy 12:30 pm
• Retrospective analyses of clinical tumor samples have identified the TGFβ pathway as a potential contributor to primary resistance to checkpoint inhibition therapy • Selective inhibition of TGFβ1 activation with SRK-181 induces profound combination treatment effects with anti–PD-1 on tumor growth in checkpoint inhibition therapy-resistant tumors • TGFβ1 isoform specificity of SRK-181 results in improved…Read more
day: Day Two
Panel Discussion: Debating the Best Approach to Target TGF-ß 10:45 am
• Which TGF-ß isoform to target to maximize therapeutic potential in IO and minimize adverse risk • Combination approaches vs monotherapy? • Is there one therapeutic approach with greater potential than others?Read more
day: Day One